UniQure Shares Are Up After Low-Dose Cohort Data From Huntington's Gene Therapy Trial
UniQure Shares Are Up After Low-Dose Cohort Data From Huntington's Gene Therapy Trial
在亨廷顿基因治疗试验的低剂量队列数据公布后，UnQure股价上涨
- UniQure N.V. (NASDAQ:QURE) announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase 1/2 trial of AMT-130 gene therapy for Huntington's disease.
- Six of the ten enrolled patients received AMT-130, and four received an imitation surgical procedure in this randomized, blinded clinical trial in the U.S.
- AMT-130 was generally well-tolerated in treated patients at the lower dose of 6x1012 vector genomes.
- No serious adverse events related to AMT-130 were reported in these patients.
- Related: Mizuho Comments On UniQure's Upcoming Low-Dose Huntington's Gene Therapy Trial Data.
- Measurements of CSF NfL, a key biomarker of neuronal damage, increased as expected following the AMT-130 surgical procedure and approached baseline at 12 months.
- Measurements of mHTT protein in the CSF of evaluable treated patients showed decreases compared to baseline through 12 months.
- Biomarker and clinical data, including 24-month follow-up in the low-dose U.S. cohort and 12-month follow-up in the high-dose U.S. cohort expected in 1H of 2023.
- Price Action: QURE shares are 24.40% at $19.15 during the market session on the last check Thursday.
- UniQure N.V. (NASDAQ:QURE) announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase 1/2 trial of AMT-130 gene therapy for Huntington's disease.
- Six of the ten enrolled patients received AMT-130, and four received an imitation surgical procedure in this randomized, blinded clinical trial in the U.S.
- AMT-130 was generally well-tolerated in treated patients at the lower dose of 6x1012 vector genomes.
- No serious adverse events related to AMT-130 were reported in these patients.
- Related: Mizuho Comments On UniQure's Upcoming Low-Dose Huntington's Gene Therapy Trial Data.
- Measurements of CSF NfL, a key biomarker of neuronal damage, increased as expected following the AMT-130 surgical procedure and approached baseline at 12 months.
- Measurements of mHTT protein in the CSF of evaluable treated patients showed decreases compared to baseline through 12 months.
- Biomarker and clinical data, including 24-month follow-up in the low-dose U.S. cohort and 12-month follow-up in the high-dose U.S. cohort expected in 1H of 2023.
- Price Action: QURE shares are 24.40% at $19.15 during the market session on the last check Thursday.
- UnQure N.V.纳斯达克公司(Temasek Holdings：QUURE)宣布了正在进行的AMT-130基因疗法治疗亨廷顿病1/2期低剂量队列试验的10名患者的安全性和生物标志物数据。
- 在美国的这项随机、盲目临床试验中，10名入选患者中有6名接受了AMT-130，4名接受了模拟外科手术。
- 在较低剂量的6×1012载体基因组治疗患者中，AMT-130的耐受性通常很好。
- 在这些患者中，没有与AMT-130相关的严重不良事件的报道。
- 相关： 瑞穗对UniQure即将发布的小剂量亨廷顿基因疗法试验数据的评论.
- 脑脊液NFL是神经元损伤的关键生物标志物，在AMT-130手术后，其测量结果如预期般增加，并在12个月时接近基线。
- 可评估的治疗患者的脑脊液中mHTT蛋白的测量结果显示，在12个月中与基线相比有所下降。
- 生物标记物和临床数据，包括低剂量美国队列的24个月随访和预计2023年上半年的高剂量美国队列12个月的随访。
- 价格行动：在周四最后一次检查的市场时段，Qure的股价上涨了24.40%，至19.15美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
风险及免责提示
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
风险及免责提示
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
抢沙发
0 0 0
赞大爱笑哭社会社会Emm心碎怒
轻触选择心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧
点击这里分享给好友
暂无评论，快来抢沙发吧！